The Act requires the standard to ensure "not more than a one in a million risk of any adverse health effect" or "shown to produce no adverse health effects, incorporating a margin of safety of at least 1,000" (sections 614 [a] 
[2][A] and [B]). It further defines reasonable certainty of no harm as "no harm will be caused to members of the general population or any vulnerable population by aggregate exposure to the cosmetic or ingredient, taking into account possible harmful effects from -(a) low-dose exposures to the cosmetic or ingredient; (B) additive effects resulting from repeated exposure to the cosmetic or ingredient over time; or (C) cumulative exposure resulting from all sources, including both the cosmetic or ingredient and environmental sources" (section 611[9]).
Under the proposed Act, the US Secretary of Health and Human Services ("the Secretary") would determine for each ingredient an allowable exposure that meets the safety standard. In determining this, the Secretary must consider whether the substance is "a known or suspected neurological or immunological toxicant, respiratory asthmagen, carcinogen, teratogen, or endocrine disruptor, or 
have other toxicity concerns, including reproductive or developmental toxicity" (section 616[a][2]

Introduction
This article examines the proposed Safe Cosmetics and Personal Care Products Act (H.R. 1385 Act (H.R. , 2013 as it relates to cosmetic safety evaluations. In particular, it examines the potential new evaluation requirements, and it estimates the costs and animal use under those proposed new requirements. It also looks at the Act in the context of sweeping changes now under way in the area of chemical safety testing (which includes cosmetic safety testing). For decades, chemical safety testing has relied on fairly standard laboratory tests, including animal tests, but efforts are now under way to develop high-throughput in vitro methods combined with computer models that can rapidly and more accurately predict human response. How the timing of any new test requirements dovetails with the development of these new test methods is key to assessing potential impacts of the Act.
[D]). The Act defines reproductive or developmental toxicity as "…can contribute to biologically adverse effects on the development of humans or animals, including effects on the female or male reproductive system, the endocrine system, fertility, pregnancy, pregnancy outcomes, or modifications in other functions of the body that are dependent on the integrity of the reproductive system as well normal fetal development" (section 611 [10] ).
The Health and Human Services agency designated by the Act to implement the new program is the Food and Drug Administration (FDA), which is the agency that currently oversees cosmetics safety in the US. In the US, cosmetics currently are regulated under the Federal Food, Drug, and Cosmetic Act and the Fair Packaging and Labeling Act. Neither act requires testing or pre-market approval of finished cosmetic products or cosmetic ingredients, except for color additives. UV filters and some finished products (for example, anti-perspirants) are regulated as drugs and require pre-market approval.
Although pre-market approval currently is not required for most cosmetics, manufacturers are still legally responsible for the safety of their products and the ingredients in them. Current law does not mandate specific tests to substantiate the safety of ingredients or finished products, but the FDA issued an advisory in 1975 that remains its advice today: "the safety of a product can be adequately substantiated through (a) (Federal Register, March 3, 1975, page 8916) .
reliance on already available toxicological test data on individual ingredients and on product formulations that are similar in composition to the particular cosmetic, and (b) performance of any additional toxicological and other tests that are appropriate in light of such existing data and information"
The safety standard proposed in the Act follows the traditional approach to toxicology that applies standard protocols to measure no observed adverse effect levels (NOAEL) and extrapolates to levels that presumably provide a specified certainty, by applying factors that consider individual variability, age, interspecies correlation, and other variables.
Where the proposed standard differs from current practice is its application of full toxicological evaluations to all ingredients. Traditionally for cosmetics, the NOAEL is derived only for general systemic toxicity, and normally only for ingredients intended to be biologically active, a small percentage of ingredients (see Section 2.1.1). Many ingredients have such a low toxicological profile that determining the NOAEL normally would not be considered necessary. At face value, the proposed Act could be interpreted to require NOAEL for carcinogenicity and reproductive toxicity, as well as for systemic toxicity. However, a NOAEL does not apply for carcinogenicity or reproductive toxicity for cosmetics, because no level of these risks is considered acceptable in a cosmetic. If any such risk is detected, the substance is not used as a cosmetic ingredient.
Potential for animal testing under the proposed Act
The proposed Act, if passed in the next couple years, would involve increased animal testing for cosmetic ingredients. This is because it would require more long-term safety evaluations, which are animal methods, than under current recommended practice. Current recommended practice is described in Section 2.1.1, and evaluations under the proposed Act are described in Sections 3.1 and 3.2. The Act (section 624, "Animal Testing Alternatives") includes language that requires alternative test methods "where practicable," but alternative test methods for long term studies are not expected to be available for about 10 years (see Section 3.7).
In contrast with the proposed US bill, the new European Union (EU) Cosmetics Regulation, Regulation EC 1223/2009, mandates the use of alternative methods for the toxicological assessment of new cosmetic ingredients (EC, 2009a) . Article 18(1a, b) of that Regulation prohibits marketing cosmetics products containing ingredients that "have been subjected to animal testing using a method other than an alternative method." This animal testing ban was implemented in three phases that were completed in 2013.
The ultimate impact of the proposed US Act on animals depends on the proposed Act's timeline (see Section 3.7) and when this timeline intersects the final development of nonanimal methods, including high-throughput test methods. The Act specifies a timeline for evaluating cosmetic ingredients that would stretch over decades if today's methods are used. This is because of the sheer number of cosmetic ingredients used in finished products: thousands of existing cosmetic ingredients, with hundreds of new ingredients introduced every year, as discussed in Section 3. Within about 10 years, however, high-throughput computer/in vitro test methods, which have been under development for several years now, are expected to be available for even the most complex toxicology tests. Toxicologists have likened the development effort to the scale of the Human Genome Project, which took 13 years to complete.
In the US, the new frontier for toxicology is framed in Toxicity Testing in the 21 st Century, A Vision and a Strategy (NRC, 2007) . That document identifies limitations of the current risk assessment process, in which few chemicals can be tested, with in vivo procedures that are expensive and of questionable relevance to heterogeneous human populations. The document proposes "a new toxicity-testing system that evaluates biologically significant perturbations in key toxicity pathways by using new methods in computational biology and a comprehensive array of in vitro tests based on human biology" (NRC, 2007) .
To further this vision, the US Environmental Protection Agency (EPA), the National Institute of Health Chemical Genomics Center (NCGC), the National Toxicology Program, and the FDA have joined in a partnership called Tox21 (http://www. ncats.nih.gov/research/reengineering/tox21/tox21.html). Important advances are the NCGC's robotic screening and informatics platform, which can screen thousands of chemicals per day for toxicological activity in cells, and EPA's ToxCast program, which uses high-throughput screening tests with the aim of both understanding the mechanism of toxicity and selecting the most concerning substances for further testing. ToxCast details, including the list of substances screened to date and early phase results, are available at http://www.epa.gov/ncct/toxcast/.
Because of their low toxicological profile, most cosmetic ingredients could be expected to pass the high-throughput screen-cost estimates are reasonable. Details on the methodology for each analysis are discussed in the section for that analysis.
Test data is the proprietary data of the company conducting the test and, historically, it has been unavailable to the public. Two pieces of legislation from the EU have created new public databases, making the analyses in this article possible: -REACH: In 2007, the EU implemented the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH, Regulation EC 1907 legislation (EC, 2006) . REACH requires safety evaluations of all chemicals produced in quantities greater than 1 ton/year, with the required evaluations dependent on production volume. The agency overseeing REACH is the European Chemicals Agency (ECHA). As part of the REACH program, ECHA has created a public database of chemicals registered under REACH, including the safety dossiers, with test details, for each chemical. This database is available at http://echa.europa.eu/web/guest/information-onchemicals/registered-substances -EU Cosmetics Regulation (Regulation EC 1223 replaces the previous Cosmetic Directive 76/768/EEC and amendments): As part of this legislation (EC, 2009a) , the European Commission (EC) established the CosIng database of cosmetic ingredients. This is the most comprehensive public database of potential cosmetic ingredients. The CosIng database is available at http://ec.europa.eu/consumers/cosmetics/ cosing/ In addition to the raw data available in the EU databases, the experience gained by the EU through these laws gives valuable insight into potential testing under the proposed Safe Cosmetics Act. Where this experience may be relevant, it is included in this article.
Constraints
This article focuses on proposed new evaluations for cosmetic ingredients. The proposed Act also gives the FDA discretion to require evaluations for finished cosmetic products under certain circumstances (section 617 [b] [2] of the Act), and the Act also briefly mentions ecotoxicity testing (section 615 [a] [2][C] of the Act). The language in the Act regarding finished cosmetic product testing and ecotoxicity testing is not sufficient to allow analysis here, so these are not considered further.
As noted previously, any evaluations would depend on the implementing regulations. In this paper, we have assumed that implementing regulations would minimize the use of the most cost-intensive, animal-intensive tests (for example, the twogeneration reproductive toxicity test). We note, however, that the stipulation of "reasonable certainty of no harm" and the requirement to prove "not more than one in a million risk of any adverse health effect" could be interpreted much more stringently than assumed in this paper, leading to higher animal use and costs than presented here.
Current testing practice
The first step in this analysis is to understand the current practice of cosmetics testing, including estimates of the current ing tests, with only a small percentage triggering a red flag due to potential for biological activity or reactivity. About 2% of cosmetic ingredients are reactive or biologically active, with most of those being hair dyes, preservatives, colorants, and UV filters (see Section 2.1.1). High-throughput methods, once available, could rapidly advance cosmetics safety testing.
The proposed Act, at face value, departs from the approach presented in Toxicity Testing in the 21 st Century, treating all ingredients as substances of concern and requiring full evaluations for all ingredients. Effectively, it drops the concept of screening chemicals and goes directly to full evaluations. If that approach prevails for cosmetics, the advances in high-throughput screening could have less effect on cosmetics safety testing.
Rationale for the Act
Cosmetic ingredients have a history of generally safe use, although individual adverse reactions to cosmetics and personal care products do occur. Cosmetic ingredients are used precisely because they have a low toxicological profile, so are less likely than many substances to be a problem. The rationale for the Act is not stated in the Act, but it likely is the "precautionary principle," which holds that, in the face of uncertainty, assume the worst case and act accordingly.
The precautionary principle does not imply "by any means." The EU's Cosmetics Regulation, for example, specifically invokes the precautionary principle as a guiding principle, and it also bans animal testing as a means to follow it. The proposed Act would initially involve expanded animal testing. A consideration beyond the scope of this article is whether such expanded testing is justified for cosmetics.
Article organization and methodology
To estimate possible impacts, we must first understand current conditions. This analysis begins, therefore, by reviewing current cosmetics safety testing in the US, including estimates for current costs and animal use. This information is presented in Section 2.
The proposed Act does not specify a testing program; rather, it specifies a safety standard and requires the FDA to determine for each ingredient the allowable exposure that meets this standard. Section 3 looks at a range of testing programs that might fulfill this requirement and estimates the costs and animal use under each. As part of Section 3, we look at the proposed Act's timeline in detail to see how that may affect costs and the use of animals.
The integrity of this analysis depends on the integrity of the data sources that are the basis for the animal and cost estimates. For this reason, we used primary data sources wherever possible. To obtain estimates of animals used in tests, for example, we examined test dossiers for studies reported in 2012. As reality checks, we cross-checked these numbers with the minimum number of animals specified in the test protocols, with published secondary reports, and with interviews with persons having direct knowledge. For test costs, we obtained current cost estimates directly from laboratories. We compared those with previously published studies of costs, adjusted for inflation to 2013. They compared well, giving confidence that the number of animals and current costs. This provides the baseline for comparing the potential impacts of the proposed Act.
Current cosmetic ingredients testing
In the US, current animal testing for cosmetics is almost exclusively for new ingredients. Safety testing guidelines and safety dossiers for individual cosmetic ingredients reveal details about typical safety testing, as described in this section. This information, paired with estimates of the number of new ingredients each year, allows estimates of the current annual cost and number of animals for cosmetics testing in the US.
Because the US currently does not specify safety tests for cosmetics ingredients, its laws do not determine safety testing for ingredients developed outside the US and then imported into the US. Under the proposed Act, however, expanded safety evaluations would apply to imported ingredients as well as to those developed in the US, increasing animal use and costs worldwide. For this reason, this section estimates current animal use and cost not just in the US, but also worldwide for testing new ingredients, since that baseline will be important when comparing the effects of the proposed Act in Section 3.8. Providing a worldwide estimate also acknowledges that cosmetics in the US use ingredients developed globally, and testing on those ingredients should be included, regardless of where the testing occurs.
Typical safety testing
Cosmetics companies are legally responsible for the safety of their products marketed in the US. For most ingredients, safety tests are not stipulated by law or regulation, but industry and regulatory guidance documents give recommended evaluations, summarized in Tables 1 and 2 . Guidance documents generally recommend that companies evaluate all cosmetic ingredients for at least the following health effects, called health endpoints (Tab. 1): -Eye irritation/corrosion -Skin irritation/corrosion -Skin sensitization -Skin penetration -Mutagenicity/genotoxicity -Acute toxicity (the effect from a single dose) As noted in the EU's primary guidance document for cosmetics testing, prepared by the Scientific Committee on Consumer Safety (SCCS), "A scientifically sound safety evaluation, based on less data than those mentioned above [same as bullets above], becomes quite impossible" (SCCS, 2010) . Although written for the EU, the SCCS guidance document is also recommended by the FDA as a guidance document for cosmetics testing in the US (FDA, 2012) .
Beyond these basic tests, considered a first tier of tests, guidance documents emphasize that the need for further testing can only be determined on a case-by-case basis. The SCCS and the EU's Standing Committee on Cosmetic Products (SCCP) give general guidelines for when it may be appropriate to consider a second tier of tests. Summarized in Table 2 , second tier tests may be appropriate, for example, for ingredients for which skin penetration tests indicate potentially significant systemic absorp-Ing database of cosmetic ingredients lists a total of 152 colorants, 56 preservatives, and 26 UV filters, out of about 20,000 total ingredients, indicating about 1% of cosmetic ingredients fall into the category of biologically active ingredients. -Hair dyes: Nohynek et al. (2010) note these are the most reactive of cosmetic ingredients. They are regulated in the EU, with safety tests specified (SCCS, 2010) . The CosIng database lists 220 hair dyes, or about 1% of ingredients. For these special cases, further recommended testing always includes a repeated dose toxicity study to identify a no observed adverse effect level (NOAEL). The preferred repeated dose study is the subchronic (90-day) study (SCCS, 2010; SCCP, 2012) .
Other tests identified as potentially relevant for these special cases are the prenatal developmental toxicity study (OECD tion or for ingredients that may be swallowed in a significant amount. Guidance documents recommend that all available data be considered, in a weight of evidence approach, before resorting to new animal tests, and note that decisions about further testing should take into account exposure, use of the product, physico-chemical structure of the ingredient, experience with similar ingredients, and other known information (SCCS, 2010; SCCP, 2012) .
A small percentage of ingredients are specifically regulated in either the US or EU, and these have official testing guidelines: -Ingredients intended to have biological activity: Most ingredients in this category are colorants, preservatives, and UV filters. The EU regulates colorants, preservatives, and UV filters; the US regulates colorants and UV filters. The EU's Cos- Further genotox c ty When: If cons derab e ora uptake can be expected or f sk n X X penetrat on s s gn ficant, tak ng nto account the tox co og ca profi e of the substance and ts chem ca structure.
Prenata deve opmenta tox c ty When: If sk n penetrat on s s gn ficant (CIR). If con-X X X s derab e ora uptake can be expected or f sk n penetrat on s s gn ficant, tak ng nto account the tox co og ca profi e of the substance and ts chem ca structure (SCCS, 2010) . Two-generat on reproduct ve tox c ty When: If cons derab e ora uptake can be expected or f sk n X X penetrat on s s gn ficant, tak ng nto account the tox co og ca profi e of the substance and ts chem ca structure.
Carc nogen c ty When: If a mutagen c ty test s pos t ve (CIR). If con-X X X s derab e ora uptake can be expected or f sk n penetrat on s s gn ficant, tak ng nto account the tox co og ca profi e of the substance and ts chem ca structure (SCCS, 2010) .
Tox cok net cs
When: If sk n penetrat on s s gn ficant or f cons derab e ora X X uptake can be expected, tak ng nto account the tox co og ca profi e of the substance and ts chem ca structure (SCCS, 2010) .
1 Cosmetic ngredient Review (C R) minimum data requirements for reviewing ingredient safety as reported in Corbett et al (1999) 2 SCCP (2012) refers readers to SCCS (2010) for guidance so we can infer that the SCCS (2010) guidelines are recommended guidelines for SCCP (2012) too One difference is that SCCP (2012) SCCP (2012) recommends the subchronic toxicity study as part of a basic (first tier) data set For SCCP (2012) therefore the subchronic toxicity study is also listed in Table 1 as one of the first tier tests An evaluation can also be done based on weight of evidence, in which the safety assessor reviews all existing data and experience to assess the safety of an ingredient. The available data must be sufficient for such an approach, and the approach must be thoroughly justified. The weight of evidence approach, too, is encouraged by regulatory agencies to reduce the need for new testing.
The EU's REACH testing program gives us insight into the frequency of use of estimation techniques and the weight of evidence approach. As part of the REACH program, the European Chemicals Agency (ECHA) compiled these data for studies contained in 1,504 chemical safety dossiers (ECHA, 2011) . Table 4 shows their frequency of use for eye irritation, skin irritation, skin sensitization, acute toxicity, and mutagenicity (based on Table 4 of ECHA, 2011) . The data show that the read-across technique was used in 20% to 23% of studies for most health endpoints. The exceptions were the in vitro skin and eye irritation tests, for which the percentages were 7% and 11.9%, respectively. The weight of evidence approach was used in 6.6% to 13.7% of studies, depending on the health endpoint. Since the first requirement of REACH is "gathering all existing information," the dossiers for many substances contain tens of studies for each endpoint (Rovida et al., 2011) . The percentages in Table 4 are calculated on all studies that have been presented, rather than on the number of substances.
The REACH dossiers were for high-volume chemicals (>1,000 tons/year). Less than 3% of cosmetic ingredients are in this category (see Section 3.3, later in this article), so these REACH data may not be representative of cosmetics ingredients, in particular for plant ingredients. Plant ingredients may be especially suited to read-across estimates and to comparative analysis to plant extracts with a traditional history of use as food (Nohynek et al., 2012) . The CosIng database indicates that plant ingredients comprise about 30% of cosmetic ingredients, so the percentages of estimation techniques for cosmetic ingredients overall may be higher than that for REACH highvolume chemicals.
TG 414), two-generation reproductive toxicity study (OECD TG 416), carcinogenicity study (OECD TG 451 or 453), and toxicokinetic study (OECD TG refers to Organisation for Economic Co-operation and Development Test Guidelines, which are international standard methods for chemical safety testing). Again, guidance documents emphasize the need for additional evaluations to be considered on a case-by-case basis.
Guidelines do not necessarily represent actual practice. A 2011 review of safety dossiers for EU-regulated cosmetic ingredients gives insight into actual practice (Vinken et al., 2011) . This review looked at repeated dose studies in dossiers for 220 cosmetic ingredients regulated under the EU Cosmetics Directive (now the EU Cosmetics Regulation) -primarily ingredients in Annexes IV (colorants), V (preservatives), and VI (UV filters). Because these are regulated ingredients, their chemical safety dossiers should include repeated dose studies according to SCCS (2010) guidelines, including the specification for subchronic (90-day) toxicity studies. Table 3 shows the actual repeated dose studies performed. The most frequently run repeated dose tests were the subchronic study, included in 54% of the dossiers, and the prenatal developmental toxicity study, included in 56% of the dossiers; 30% of the dossiers had no repeated dose study information.
Going forward in this analysis, the percentages in Table 3 are used to help estimate the number of tests currently run on new cosmetic ingredients in special categories, because the percentages reflect real practice. These categories represent a small percentage of cosmetic ingredients, but the additional tests are animal intensive, so their contribution to the total is significant.
Techniques to reduce testing
An evaluation for a health endpoint does not necessarily mean testing. If a new ingredient is in a chemical group with known properties, the new ingredient's properties sometimes can be estimated based on the known properties of that group, a technique called read-across. Estimation methods are accepted as scientifically sound and are encouraged by US regulatory agencies. Chron c (>1 year) repeated dose tox c ty study 17 8%
Carc nogen c ty study 15 7%
Prenata deve opmenta tox c ty study 124 56%
Two-generat on reproduct ve tox c ty study 10 5%
No repeated dose stud es 66 30%
1 Data from Vinken et al (2011) a study that examined dossiers for 220 cosmetics ingredients regulated by the EU The regulated ingredients are intended to be biologically active and typically are colorants preservatives and UV filters 2 44 of the subacute tests were in addition to the subchronic study for the ingredient; only 10 ingredients (5% of ingredients) were tested only in the subacute study ine the state of the science for alternative methods for cosmetics, as the basis for future testing without the use of living vertebrate animals (Basketter et al., 2012) . Once high-throughput and other alternative methods are available, expected in about 10 years, cosmetics ingredients can be evaluated rapidly, likely without the need for animals. Table 4 may be high, including invalid use of the techniques. Despite the limitations of the ECHA percentages, they are the best available data currently, and are used in this analysis to estimate the use of read-across and weight of evidence techniques for eye irritation, skin irritation, skin sensitization, acute toxicity, and mutagenicity.
Cost per test
ECHA also reports the percentages of read-across and weight of evidence for repeated dose studies. For new cosmetic ingredients, however, Adler et al. (2011) report that estimation methods are rarely used for repeated dose tests, "partly due to the limited ability to read across to very novel ingredients and partly because a robust evaluation requires a large amount of animal data on structurally similar materials, which is rarely available." The EU's ban on animal testing for cosmetic ingredients precludes the use of new repeated dose tests for any ingredient marketed in the EU. The number of very novel ingredients may decline, therefore, until alternative methods are available to replace the repeated dose tests. This may mean that new ingredients are more likely to be variations of compounds whose toxicity history is already understood, allowing use of read-across and weight of evidence techniques to substantiate safety. Offsetting this, cosmetics and ingredients not marketed in the EU may still undergo these tests; in fact, some countries require animal testing. Consistent with Adler et al. (2011) , this analysis assumes estimation techniques are not used for repeated dose tests for new cosmetic ingredients.
As noted in Section 1.2, major efforts are under way to develop faster, more predictive chemical safety tests that may eliminate the need for animal testing. In the US, the framing document for this effort is Toxicity Testing in the 21 st Century (NRC, 2007) , which envisions the use of high-throughput in vitro screening tests on all chemicals with the aim of both understanding the mechanism for toxicity and immediately selecting the most concerning substances for further testing. Recently, internationally recognized experts met in a workshop to exam- Table 4 doses plus the negative control. The added cost from the preliminary dose-finding study is about $ 10,000 per test item. One pre-dose finding study can be used for all long-term studies for the same substance and therefore it should be counted only once per substance. -Analytical determinations: Good Laboratory Practice (GLP) studies require that concentrations be measured by proper analytical methods. Extra costs include the validation of the analytical method and the measure of each solution that is prepared and used. This cost strongly depends on the analytical technique. Not all ingredients would require testing. Some could be evaluated through read-across and weight of evidence techniques. These require the use of existing studies. If an existing study is published and does not contain a disclaimer prohibiting its use without permission, it probably can be used free of charge. For other studies, the safety assessor must obtain permission to use the studies from the owners of those studies. Called Letters of Access, these can be more than half the price of the study itself. The cost estimate for a read-across or weight of evidence evaluhave provided sufficient capacity to keep costs from rising. For our later analysis of potential costs under the proposed Act, we will assume a similar pattern: that is, that costs will remain steady, except for inflation, for the 10 year period of the analysis. For this reason, we will not need a present value analysis to account for price changes other than inflation. Table 5 shows the costs that an average contract laboratory charges for the test only. The following additional services are typically required in conjunction with the test: -Study management/administration and preparation of the toxicology advisory: The cost for each test is increased by at least 50% to account for administrative/management costs plus the toxicology advisory that is always added to come to a practical conclusion in the toxicological assessment of the test item. -Pre-dose finding study for long-term studies: Long-term studies are preceded by a preliminary study, which is used to find the subtoxic doses. These pre-dose finding studies (also called range-finding studies) are usually 15-day repeated dose studies that are performed on the same number of animals at three 
Animal use per test
Historically, the number of animals per test has been calculated using official documents such as Hofer et al. (2004) and van der Jagt et al. (2004) . Now, a more precise evaluation is possible through ECHA's public database of REACH registration dossiers. This database is quite exhaustive, especially for studies ation must include costs for the following: the demonstration that such a technique is acceptable for the substance; an evaluation of the substance using the estimation techniques; and the possible purchase of Letters of Access. The analysis here assumes that an evaluation through estimation techniques is onehalf the cost of an evaluation involving laboratory testing. numbers usually are not included in final study reports. Without reported numbers, we cannot include them in this analysis, because the number may be very variable from study to study. Estimating the numbers by adding a fixed percentage to the final calculation may lead to a higher level of error than not considering it at all, so we do not include such an adjustment.
The reproductive toxicity studies (OECD TG 414 and 416) involve parent animals and their offspring. OECD TG 416 involves the parent generation (P) and their children (F1) and grandchildren (F2). Parent (P) and children (F1) undergo the same dosing and are euthanized once their pups are weaned. The grandchildren (F2) are euthanized after weaning. OECD TG 414 involves pregnant females that are dosed and then euthanized just before delivery, and the fetuses are then examined for toxic effects. To count animals in these tests, investigators historically have used two methods: some have counted only the parent animals, and some have counted both the parents and the offspring. In van der Jagt et al. (2004), for example, only parents are counted for both OECD TG 414 and OECD TG 416; in Hofer et al. (2004) , parents and offspring are counted for both 414 and 416; and in Cooper et al. (2006) , parents and offspring are counted for OECD TG 416, and only parents are counted for OECD TG 414. Counting offspring is now the official mode in the EU, adopted in EU Directive 63/2010, which considers as experimental animals all animals that are bred for the purposes of scientific experiments plus fetuses that are in the last third of their normal development. The US has no official counting method.
This analysis follows the convention of Hofer et al. (2004) and EU Directive 63/2010 and counts offspring, given that F1 offspring undergo the same test protocol and conditions as parents in OECD TG 416 and all offspring are euthanized in both OECD TG 414 and OECD TG 416. For OECD TG 414, only the female parent is counted, because the study begins with pregnant females.
The extended one generation reproductive toxicity test, OECD TG 443, is recent and its applicability as a replacement for the full two-generation study (OECD TG 416) is still under discussion. The number of animals in Table 6 is estimated from the OECD guideline, as there is still not enough data to evaluate the real number.
Rat is considered the species of choice for all studies but eye irritation and studies that are based on dermal exposure. To calculate the total number of rats used for a reproductive toxicity study, this analysis assumes a litter size of 12 pups per pregnant female. The average of 12 accounts for possible reduction caused by an effect of the tested chemical or the accidental death of any pregnant rats. Note that an average litter size of 12 likely underestimates the real litter size, which is typically about 15 in REACH dossiers. In previous estimations, a lower number was used (Rovida and Hartung, 2009) , which derived from current practice at that time. Probably, compared with the past, new studies are generally performed at subtoxic doses and therefore delivery usually is not affected in terms of reduced pups per litter. Sometimes, a higher number of resorptions is recorded at the highest dose, but usually nothing more.
that have been performed after 2010. In particular, there is good standardization in the protocols that strictly follow the OECD guidelines.
To evaluate the typical number of animals per test, studies were selected through eChemPortal (http://www.echemportal. org), where search by OECD guideline is possible. For each endpoint, the search included the corresponding OECD guideline and the report year of 2012, assuming that the most recent year may provide higher reliability that the study was performed according to the latest Good Laboratory Practice (GLP) requirements. The search returns a list of chemicals with their CAS number. To obtain details on animal use, CAS numbers were randomly selected and then searched in the ECHA database of registered REACH substances (http://echa.europa.eu/ web/guest/information-on-chemicals/registered-substances). This provided links to the REACH registration dossiers for those chemicals. The dossiers include the study details, making it possible to get the species and number of animals used for that specific study. Table 6 shows the animal numbers reported for studies for each OECD guideline. For comparison, it also shows the minimum number of animals specified in the OECD guidelines for each method. Long-term studies generally use more than the minimum to assure enough animals to meet the minimum requirement through to the end of the experiment. Also, OECD guidelines usually call for a negative control group as a minimum control; in practice, some studies include both a positive and a negative control group or two negative control groups. For OECD methods where the REACH dossiers did not provide animal counts, this analysis used the minimum specified in the OECD guidelines.
Most, if not all, long-term studies use the following additional animals, which normally are not reported: -Animals in pre-dose finding studies: As noted in the costs section, long-term studies are preceded by a preliminary study, which is used to find the subtoxic doses. These pre-dose finding studies (also called range-finding studies) are usually 15-day repeated dose studies that are performed on 15 animals at three doses plus the negative control, using up to 80 animals. One pre-dose finding study can be used for all long-term studies for the same substance and therefore it should be counted only once per substance. -Satellite animal groups: For long-term studies using small animals such as rats (which is the case for most cosmetics safety tests), limited blood samples can be drawn. There are humane limitations to the amount of blood taken from an animal each time; significant blood loss and trauma also can affect the study results. In consideration of this, studies use satellite groups, which are dosed with the test substance in the same manner as the main group (usually only the highest and control doses), but they have no additional investigation that may cause stress, like withdrawal of blood samples. They are used for additional investigation in case of doubtful outcomes and to replace animals in the main study that unexpectedly die. Logically, these animals should count, because they undergo testing and are euthanized in the end, too. However, their Tab. 3 in Section 2.1.1), reflecting that actual practice may differ from the guidelines. For subchronic toxicity, for example, the 3% of ingredients for which the test may be recommended is multiplied by 54%, which is the percentage of dossiers for that category of ingredient that actually contained the subchronic toxicity study. The result is 3% x 54% = 1.6% of ingredients in that category estimated to undergo the subchronic toxicity study. -Read-across and weight of evidence techniques are used at the percentages indicated in the REACH dossiers (see Tab. 4 in Section 2.1.2). The cost for a read-across or weight of evidence evaluation is about one-half the cost of the corresponding laboratory test (see Section 2.1.3, "Cost Per Test"). As shown in Table 7 , this yields an estimate of 2,700 animals annually for ingredient evaluations in the US. The cost estimate is about $ 3.2 million for laboratory tests and $ 600,000 for read-across/weight of evidence evaluations. As noted in Section 2.1.3, laboratory test costs are for only the test itself. The cost for management/administration/analysis of the test and preparaEye irritation in vivo and skin sensitization according to OECD TG 429 (Local Lymph Node Assay, or LLNA) soon can be fully replaced by in vitro alternatives at about the same price.
Number of new cosmetic ingredients annually
A primary source for the number of new ingredients each year is the Personal Care Products Council (PCPC), which assigns the official INCI (International Nomenclature Cosmetic Ingredient) names to new ingredients. About 500 to 700 new cosmetic ingredients receive INCI names each year (Personal Care Products Council, 2012 Table 4 in this article for details No REACH data were available for skin penetration and phototoxicity For these an estimate of 30% is used which is in the midrange of known percentages for the other endpoints For repeated dose studies estimation techniques are rarely used for new ingredients (Adler et al 2011) so 0% is used here 3 Calculated as (60 new ingredients) x (% ingredients evaluated for this endpoint) x (1 % evaluated by RA/WOE) The result is less than 1 for tests that are typically not concluded in one calendar year or that are rarely conducted 4 For the derivation of the costs and animal numbers see Section 2 1 3 and 2 1 4 respectively 5 Calculated as (60 new ingredients) x (% ingredients evaluated for this endpoint) x (% evaluated by RA/WOE) x (50% of lab test cost) As noted in Section 2 1 3 this analysis assumes the unit cost of a RA/WOE evaluation is about one half the cost of the corresponding laboratory test the categories that undergo the second tier of testing, not all years would include the more intensive repeated dose tests. The average of these two years is 3,408 animals. These EU numbers suggest that the US estimate in this analysis (2,700) is reasonable. Remember that the EU published more than triple the cosmetic patents of the US in 2005; there have been no market shifts since 2005 that would significantly change this pattern. At the least, we can see that the scale of animal testing for new ingredients in the US is on the order of thousands per year, rather than tens of thousands.
As a further reality check, we directly asked people with firsthand observations -those working in testing laboratories and the USDA staff who inspect the laboratories. In an informal phone survey of three US testing laboratories and a regional supervisor of USDA inspectors (who in turn polled his inspectors), no one had seen animal testing for cosmetics for years. When asked if an annual estimate of 0 to the low thousands was a reasonable estimate, the laboratory employees and USDA supervisor answered yes (the inspectors themselves were not asked that particular question). Although not a scientific survey, these anecdotes are useful as another reality check on the estimate.
Current finished cosmetic product testing: Non-animal methods are the norm
For finished cosmetic products, current routine practice in the US involves the following safety tests, all of which are alternative, non-animal test methods: -Eye irritation: Usually tested in vitro through OECD TG 437 or 438. -Skin irritation/corrosion: Can be tested through several cellbased methods, for example, EpiSkin, or through the Cumulation of the toxicology report adds about another 50%, or about another $ 1.6 million. This results in a total annual cost estimate of $ 5.4 million. An ingredient developed in the US is not necessarily tested in the US. Similarly, US testing laboratories serve foreign companies, too. There is no easy way to account for this, but it is also not critical to account for it. Note that even if you take the most extreme assumption, that all 500 to 700 new ingredients worldwide are tested in the US, this results in an estimate of 27,000 animals and $ 54 million annually. As will be seen later in this analysis, these numbers are low compared with the estimate of animals and cost under the proposed Act, so further refining the estimate for current testing in the US is not critical.
Also, as noted previously, cosmetics in the US use ingredients developed globally. Currently, US law does not mandate specific safety tests for ingredients, so its laws are not a primary factor in the choice of safety tests worldwide. The safety evaluations mandated by the proposed Act, however, would affect safety testing worldwide. The worldwide number, therefore, is a baseline for comparing the effects of the proposed Act. If we consider testing worldwide, we can use the cost and animal estimates just given for 500 to 700 new ingredients: 27,000 animals and $ 54 million annually. Although EU law prohibits cosmetic ingredients tested on animals, those ingredients may still undergo animal tests when exported to other countries; therefore, the numbers probably need not be adjusted to deduct EU-developed ingredients.
Reality check of estimate
Under US law, laboratories that use animals for testing are inspected by the US Department of Agriculture (USDA), and the USDA inspection reports include the number of animals; however, the reports exclude mice and rats, and they do not break out the number of animals by testing purpose (for example, for cosmetics testing). The USDA reports, therefore, cannot provide supporting information for this estimate of cosmetics testing.
The European Union, however, does include mice and rats in reports and does break out animals by testing purpose. The Act clearly identifies a requirement to determine, for each ingredient, an exposure scenario that will "produce no adverse health effects." Currently, repeated dose studies are used for the derivation of the no observed adverse effect level (NOAEL), a key parameter for this determination. The preferred study is the subchronic (90-day) toxicity study (SCCS, 2010; SCCP, 2012) , because it allows a more precise estimate of the NOAEL than can be obtained from a subacute (28-day) study. In fact, any adverse effect recorded in other long term studies, for example, studies to assess carcinogenicity potential or reproductive toxicity, would prevent the ingredient from being used in cosmetic products. Under the Act, therefore, we can assume that all ingredients would need the subchronic toxicity study in order to calculate a more precise NOAEL. Currently, the subchronic toxicity study is typical only for regulated ingredients, which are about 2% of all ingredients, so new subchronic toxicity studies likely would be needed for most ingredients.
The proposed Act does not specify other tests by name; it specifies only the health endpoints that must be considered when determining the NOAEL, as quoted above. The following section looks at other toxicity tests that may be considered in order to meet this requirement.
Potential new tests under the proposed Act
OECD test methods are internationally accepted (including by the US) standard methods for chemical safety testing. All OECD test guidelines can be downloaded for free at the OECD website (http://www.oecd.org/env/ehs/testing). If additional evaluations are needed for the health endpoints specified in the Act, they would likely involve one or more of the following OECD test methods: -Genotoxicity: Genotoxicity is usually performed in vitro. In some cases, further, in vivo studies are requested if results are suspicious. Considering that cosmetic ingredients are chemicals with a very low toxicological profile, in depth investigation is usually not necessary. The European Commission Services' working group to review the status of genotoxicity testing for cosmetics concluded that in vivo tests for cosmetics are not relevant (Maurici et al., 2005) .
-Repeated Dose (Subacute/28-day or Subchronic/90-day)
Toxicity Studies: These evaluate toxic effects on organs and organ systems, including liver, kidneys, lungs, reproductive organs, central nervous system, hematopoietic system (lymph nodes and bone marrow), immune system, and endocrine system. As noted previously, repeated dose studies also allow the development of NOAELs, which would be needed under the proposed Act in order to establish the allowable exposures. For cosmetics, guidelines recommend the subchronic (90-day) study, rather than the subacute (28-day) study, because the subchronic study is better for determining a NOAEL. The Vinken et al. (2011) (Basketter et al., 2005) . The absence of animal testing for finished cosmetics can be at least partly attributed to the EU's ban on animal testing for any finished cosmetic products marketed in the EU. The ban, which took effect in 2004, spurred the development of alternative, non-animal methods. Given that alternative methods are now widely accepted in the US for finished cosmetic products, are cost competitive with animal tests, and are the only option for companies selling into the EU, no incentive exists for using animal tests for finished cosmetics. In fact, the disincentives are enough that use of animals in finished cosmetic product testing would be atypical.
Testing under the proposed Act
Under the proposed Safe Cosmetics and Personal Care Products Act of 2013, safety evaluations would be expanded for all existing and new ingredients. The FDA would determine for each ingredient an allowable exposure that meets the proposed safety standard: "not more than a one in a million risk of any adverse health effect" or "shown to produce no adverse health effects, incorporating a margin of safety of at least 1,000" (sections
614[a][2][A] and [B]).
As noted in the Introduction, the Act requires the FDA to consider whether the substance is "a known or suspected neurological (OECD TG 424 and 426) : This is a stand-alone test, but similar information can be obtained from OECD TG 416 and 443 if they include a neurotoxicity segment. This analysis assumes that, if neurotoxicity information is needed, it would be included as part of OECD TG 416 or 443 to minimize the number of animals used. OECD TG 424 or 426, therefore, is not included in any of the scenarios for this analysis. Current practice is to conduct these tests only on a case-by-case basis, taking into consideration the physico-chemical properties of the ingredient and experience. Under the proposed Act, at least a repeated dose toxicity evaluation would become necessary for all ingredients in order to determine the NOAEL. How other tests would be considered cannot be known without implementing regulations, but this analysis looks at a range of possibilities, from a minimum case of adding just the subchronic toxicity study to cases that would include more intensive studies, such as the prenatal developmental toxicity study.
As noted, the two-generation reproductive toxicity test, extended one-generation reproductive toxicity test, and carcinogenicity test are much costlier than other tests, in terms of monetary cost, time, and animal lives. Assumptions about the frequency of these tests, therefore, are the most critical assumptions in this analysis. The choices related to these tests, both in this analysis and in any legislation and regulations, will dominate the impacts.
For this analysis, we have assumed that implementing regulations would minimize the use of the most cost-intensive, animalintensive tests, such as the two-generation reproductive toxicity test. We note, however, that the Act could be interpreted much more stringently than assumed in this paper, leading to higher animal use and costs than presented here. dossiers for EU-regulated cosmetic ingredients found 54% had the subchronic study and often included a subacute study as well. Only 5% had just a subacute study. This suggests the subchronic study is the norm. (OECD, 2004b) . These documents give detailed testing protocols and recommendations for these health endpoints.
Estimated number of cosmetic ingredients
The European Union has compiled the Cosmetic Ingredient (CosIng) database, a comprehensive list of known cosmetic ingredients and their functions. The URL for this database is http://ec.europa.eu/consumers/cosmetics/cosing/. This analysis used two different types of CosIng searches to find the total number of cosmetic ingredients: an "Inventory" search and an "All" search.
-Inventory search
For this search, the search parameters were Version: 
Potential testing scenarios
This section explores a range of possible testing scenarios under the proposed Act, from a minimum case in Case 1 that would involve the current first tier evaluations plus the subchronic toxicity study, to a maximum case in Case 4, in which ingredients undergo further second-tier testing. The potential scenarios are based on current evaluation programs in the US and EU. The proposed Act would require all ingredients to have the same safety evaluation. It does not make distinctions based on toxicological profile, biological activity, volume, or other factors. The following potential testing scenarios are analyzed here:
Case 1: Subchronic toxicity study In this case, all ingredients would be evaluated for the first tier endpoints that are typical practice currently (see Tab. 1). In addition, all ingredients would be evaluated for subchronic toxicity to evaluate systemic toxicity and the NOAEL.
Case 2: SIDS with screening studies
In this case, all ingredients would be evaluated for the Screening Information Data Set (SIDS). This is an internationally accepted (including by the US), minimum test set for evaluating chemical properties, including mammalian toxicology. The reproductive/developmental screening study (OECD TG 421 or 422) would provide the only data on reproductive and developmental toxicity. A full reproductive toxicity study (OECD TG 416 or 443) would not be required; nor would the FDA require the full prenatal developmental toxicity study (OECD TG 414) . This case is based on the guidelines in OECD Manual for the Assessment of Chemicals, Section 2.2, "The Screening Information Data Set (SIDS)" (OECD, 2004a) .
Case 3: SIDS with prenatal study
The SIDS requirement for the reproductive/developmental toxicity health endpoint can also be met with the full prenatal developmental toxicity study (OECD TG 414), along with the subchronic (90-day repeated dose) toxicity test if the subchronic test examines the reproductive organs and sufficiently documents the examination. Because this case includes the full prenatal developmental toxicity study, it may better meet the requirements of the proposed Act than would Case 2. Like Case 2, Case 3 is based on the guidelines in OECD Manual for the Assessment of Chemicals, Section 2.2, "The Screening Information Data Set (SIDS)" (OECD, 2004a) .
Case 4: SCCS guidelines
All ingredients would be evaluated to the same degree as the 2% of cosmetic ingredients that currently have specific evaluation requirements in the SCCS guidelines (SCCS, 2010) . For this case, the analysis uses these guidance documents: -The SCCS's Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation (SCCS, 2010) . This gives the EU guidelines for evaluating ingredients that are specifically regulated (for example, UV filters and col-
The proposed Safe Cosmetics Act requires evaluations of ingredients that are in use in cosmetics. Not all ingredients listed in CosIng are used in cosmetics at a given time, and those that are used are constantly in flux given the frequency with which new products are created and existing ones reformulated. The number of ingredients in use will be less than the total number, but probably not by much. One online database identified about 9,000 ingredients among about 70,000 products. Given that Amazon alone lists more than 500,000 different cosmetic products, most of the CosIng ingredients are likely in use in some product over the 10-year period of this analysis. What we can say with some certainty is that the percentage in use is more than 50% and less than 100%. For the analyses here, we use a conservative 70%.
Chemicals often are categorized by production volume in regulatory programs. The EU's REACH regulations categothose without INCI names and those that are prohibited under Annex II of the EU's Cosmetics Regulation. To obtain the number of non-prohibited ingredients, the prohibited ingredients are subtracted. In both searches, the Search field was left blank to display the full database. Duplicates were identified by sorting the database, looking for duplicate names or ID numbers (CAS or EC numbers). Not all duplicate ID numbers denote duplicate substances, since the same ID number may apply to related but different substances. Each set of duplicate IDs was evaluated case-by-case to determine duplicate ingredients.
The results of the searches are shown in Table 9 . They are similar and place the number of cosmetic ingredients at about 20,000 in October 2012, when the searches were performed. A more recent Inventory search, in September 2013, shows this number is now 20,790. in the CosIng database are plant ingredients). For this analysis, ingredients less than 1 ton/year are included in the 1-10 ton/ year range for simplicity; it has no effect on the calculations. Also, REACH does not include substances of natural origin, defined in REACH as naturally occurring substances as such or extracted through specified means. Only room temperature water is allowed as a solvent. All other substances, including those extracted by solvents or by vapor must be registered if their production volume is more than 1 ton/year. Cosmetics may include food additives, which are evaluated separately from REACH but with a very similar approach.
The production volume is also important because lowvolume ingredients would be disproportionately affected by the cost of additional evaluations and testing. For very low volume ingredients, the ingredient manufacturer may choose to discontinue the ingredient rather than incur the cost of the evaluation. Estimating this effect is not possible, except to say that the number of ingredients evaluated could be less than the total number shown in the CosIng database, because marginally profitable ingredients could be discontinued in response to the Act. Since most cosmetic ingredients have small production volumes, this effect could be significant.
Impact of existing data for cosmetic ingredients
Most ingredients should have existing test results for the first tier tests that are routinely run on cosmetic ingredients: eye and skin irritation, skin sensitization, mutagenicity, and acute toxicity. To estimate existing test results for second tier evaluations, which are mainly repeated-dose tests, the following sources provide primary data: -RPA & Statistics (2002) estimated the amount of existing chemical data based on questionnaires sent to chemical manufacturers/importers and to their associations. The questionnaire asked about availability of complete data sets for the tests required under REACH. Because the questionnaire asked about complete data sets only, it does not account for chemicals that have partial data sets. As RPA & Statistics notes, this means the results underestimate the amount of existing test data. Still, these results are useful as a lower bound for the amount of existing test data (see Tab. 11). -ECHA (2011), responsible for implementing the EU's REACH program, reported statistics for existing tests submitted to meet REACH requirements. ECHA analyzed dossiers for 1,504 substances with production volumes over 1,000 tons/year and for 218 substances with production volumes of 100 to 1,000 tons/year. The analysis indicates the amount of existing data is higher than estimated in RPA & Statistics, as expected. The ECHA numbers, however, likely overestimate the amount of existing data, because the initial ECHA review of the data indicated "…the experimental data provided in the dossiers are in some cases also not sufficient to meet information requirements under REACH" (ECHA, 2011). The ECHA statistics, therefore, can be taken as an upper bound on the amount of existing data (see Tab. 11).
rize chemicals by the following production volumes: >1,000 tons/year, 100 to 1,000 tons/year, 10 to 100 tons/year, and 1 to 10 tons/year, with different test requirements for each range. Higher production volume chemicals typically have more safety data, so it is helpful to estimate the number of cosmetic ingredients by production volume. The EU's REACH and CosIng databases let us do that: ->1,000 tons/year The CosIng ingredients were checked against the REACH substance database, which gives the production volume range for each substance. For tonnage >1,000/year, 447 cosmetic ingredients were found in the REACH database. This is 2.2% of total cosmetic ingredients. All substances produced in volumes greater than 1,000 tons/year were required to be registered under REACH by November 30, 2010, so this is a near complete inventory.
-100 to 1,000 tons/year
This tonnage range was required to be registered under REACH by May 31, 2013. The REACH database has not yet been updated with all of the new dossiers. The method was to check the CosIng ingredients against the substances registered to date under REACH, and then to extrapolate to the total, assuming the ultimate number of REACH substances in this range is near the original estimate of 1,954 (Pedersen et al., 2003) . This resulted in an estimate of 270 ingredients, or 1.3% of total cosmetic ingredients.
-10 to 100 tons/year and 1 to10 tons/year
In a 2003 study evaluating REACH, Pedersen et al. (2003) estimated the percentages for these REACH tonnage ranges were 18% and 63%, respectively. Adding these to the nowknown percentages of the other tonnage ranges totals to about 84.5%, leaving 15.5% of ingredients in these lower ranges unallocated. For this analysis, the unallocated 15.5% are evenly assigned to the two lower tonnage ranges. For 10 to 100 tons/year, this gives 18% + 7.75% = 25.75%. For 1 to 10 tons/year, this gives 63% + 7.75% = 70.75%. The estimated number of ingredients can then be back-calculated by multiplying the percentage by 20,790, the known total number of ingredients in September 2013. This gives 5,353 and 14,720 ingredients, respectively, for these tonnage ranges. Table 10 shows the results, indicating that perhaps over 95% of cosmetic ingredients have relatively low production volume, less than 100 tons/year.
At the moment (August 2013), about 9,900 unique substances have been registered according to the REACH regulation for substances >1,000 tons/year and 100-1,000 tons/year. Even though this number includes intermediates and some new chemicals, it clearly exceeds Pedersen et al. (2003) 's original estimate for these tonnage ranges. However, for nonintermediate substances, a category that includes all cosmetic ingredients, Pedersen et al.'s estimates are closer to the real number of REACH registrations, giving more confidence in these numbers.
Note that REACH does not include substances with a production volume less than 1 ton/year, categories that may include many cosmetics ingredients (consider that 30% of ingredients that program. Their report did not break out the percentages of existing data for each endpoint, but this percentage lies between the lower and upper bounds from the other two reports and generally supports this as a reasonable range for ingredients produced in volumes >1,000 tons/year. Under REACH, all chemicals produced in volumes greater than 100 tons/year must be evaluated for subchronic toxicity and prenatal developmental toxicity; and those greater than 1,000 tons/year must undergo evaluations for two-generation reproductive toxicity and carcinogenicity as well. REACH - Bishop et al. (2012) reviewed the US EPA's High Production Volume (HPV) Challenge Program, which was a voluntary program for industry to provide a SIDS data set for high production volume chemicals. The data set included acute, subacute, and subchronic toxicity tests; the prenatal developmental toxicity study (OECD TG 414) and onegeneration reproductive toxicity study (OECD TG 415); and the reproductive/developmental toxicity screening tests (OECD TG 421 and 422). Bishop et al. (2012) found that industry had existing data for 27% of health endpoints in Tab Table 4 That table includes the number of existing experimental studies for each endpoint To derive the percentages here the number of existing studies is divided by the total number of substances analyzed; for example the subchronic dermal endpoint had 129 existing test results for 1504 substances or 9% Some substances had multiple studies for the same health endpoint For these the percentage above is the percentage of existing studies divided by the total number of records for substances in that tonnage range; for example the subchronic oral toxicity endpoint had 2365 records for 1504 substances; among these records were 1025 existing test studies The percentage was calculated as 1025/2365 or 43% centages of existing data without and with REACH. For existing ingredients, this analysis will use the simple assumption that 15% of ingredients have existing data for repeated dose tests. A 15% estimate is the midpoint of the range in Table 12 for ingredients in the 0-10 tons/year and 10-100 tons/year ranges, which is 95% of cosmetic ingredients. The main exception is the dermal exposure route, for which data appear to be almost non-existent (0%-3%). Oral tests can be extrapolated to the dermal route, however, so for simplicity's sake, we use 15% for the dermal exposure route, too. Keeping the assumption simple also acknowledges that choosing any number is a guess, but at least a guess within an expected range.
REACH data could potentially provide 100% of data for some endpoints, but only for about 3.5% of ingredients, so we do not consider it further here. The exception is for the reproductive toxicity screening test, for which REACH could provide data for ingredients >10 tons/year, which is about 30% of ingredients.
For new ingredients, the analysis also assumes that 15% will have available data, because some new ingredients will originate from the pharmaceutical and food industries and be fully characterized. requires a comprehensive data set only for the highest production volume substances, those over 1,000 tons/year. An important difference between the scope of REACH and the proposed Safe Cosmetics Act is that REACH addresses all chemicals, and a carcinogenic substance may still be used provided that the risk is sufficiently managed and no contact with consumers will occur. On the other hand, cosmetics are by definition used in direct contact with consumers. Consequently, some in depth investigations that are required by REACH for chemicals of concern do not apply to cosmetic ingredients simply because when a higher risk is suspected, that ingredient is not used.
Theoretically, REACH studies could provide good data sets for ingredients in the 100-1,000 ton/year and >1,000 ton/year ranges. However, most of those existing studies are proprietary, and the owner usually charges for a Letter of Access at a cost that is often more than half the cost for repeating it. If REACH data are available for cosmetic safety assessments, the REACH data could be sufficient for the higher production volume cosmetic ingredients, about 3.5% of total cosmetic ingredients (see Tab. 10 in the preceding section). For lower production volume ingredients, the REACH data could provide partial data sets. Waivers may also reduce the number of tests needed. For cosmetics ingredients, the only basis for a waiver probably would be that an exposure route does not apply. Exposure routes are the ways by which humans may be exposed to a substance: by swallowing it (the oral route), by skin contact (the dermal route), or by inhaling it (the inhalation route). The main exposure route for most cosmetic ingredients is dermal, although oral and inhalation are significant routes for some ingredients.
The Vinken et al. (2011) review of 220 cosmetic ingredient dossiers found the only exposure route tested was the oral exposure route. This reflects current standard practice in the EU, where the oral route is the primary exposure route tested for cosmetic ingredients. In the US, the choice of exposure route is less documented. US regulators generally suggest that toxicity tests use the exposure route that corresponds to the human exposure route (Nohynek et al., 2010) , but test data are usually not public, so whether this suggestion translates into practice is unknown. Rovida and Hartung (2009) estimate waivers for acute oral, inhalation, and dermal toxicity to be 10%, 50%, and 60%, respectively, assuming that oral is the main route tested. Each route includes waivers for 10% of substances for which no human exposure is likely or which are already known to be toxic and so require no further testing. For cosmetics and For phototoxicity, we assume 0.1% of existing and new ingredients have available data, because that is the percentage of ingredients that are UV absorbers. UV absorbers are regulated ingredients in the US and EU and generally undergo this testing. Other ingredients normally are not tested for phototoxicity.
In summary, we assume the following percentages for available data: -Existing ingredients: 100% for all first tier endpoints, 30%
for the reproductive toxicity screening study, 0.1% for the phototoxicity study, and 15% for other endpoints. -New ingredients: 15% for all endpoints except phototoxicity, which is 0.1%.
evaluations, which use the most animals, no validated alternative methods are available.
Limits to testing: The Act's timeline and agency capacity
The proposed Act specifies a sequence for implementing the new evaluations (Safe Cosmetics and Personal Care Products Act of 2013, section 616): Years 0 to 2: The FDA would conduct an initial review of all ingredients and place them in one of the following categories: -Ingredients that meet the safety standard without any restrictions -Ingredients that meet the safety standard, but with restrictions -Ingredients that are prohibited -Ingredients for which data are insufficient to make a determination Nearly all ingredients would initially fall into the last category, because the expanded evaluations would be new for all but about 2.2%-3.5% of cosmetic ingredients: those that are already regulated by the EU (colorants, preservatives, UV filters, and hair dyes) or those for which REACH may have sufficient data. Year 2: From the pool of ingredients without sufficient data, the FDA would create a priority list of 300 ingredients minimum and request additional information for those ingredients. Year 3 and each year thereafter: The FDA would add another 100 ingredients minimum to the list for further evaluation each year, until all ingredients were placed on the list and evaluated.
This timeline would result in the evaluation of 1,200 ingredients by year 10. Currently, the number of ingredients in the CosIng database is about 20,800. By year 10, the number of CosIng ingredients will be about 26,800 if it continues at the pace of adding 500-700 new ingredients per year. If we assume only 70% of CosIng ingredients are used in cosmetics over the 10-year period (see Section 3.3), the total number of ingredients in use will be about 18,800. If the FDA evaluates the ingredients at the rate specified in the timeline, 1,200 over 10 years, this would be about 4% of total ingredients in year 10, or about 6% of ingredients in use.
Note that the priority list would never catch up with the number of ingredients. Instead, it would fall further behind each year, because the number of new ingredients would outpace the evaluations. In year 2, for example, the list would have about 21,700 ingredients remaining to be evaluated (21,700 = 20,800 existing ingredients + 1,200 new ingredients over 2 years -300 ingredients added to the priority list). In year 10, it would have about 25,600 ingredients remaining to be evaluated (26,800 existing ingredients in year 10 -1,200 ingredients added to the priority list in 10 years).
Presumably, the authors of the bill do not intend this. It is unclear what the timeframe should be, however, given key constraints: -The capacity of existing laboratories to conduct the expanded testing.
cosmetic ingredients, this 10% for waivers does not apply, because (1) human exposure is a given for cosmetics and (2) cosmetics do not contain substances already known to be toxic. The ingredients are available precisely because they are already believed to be safe, having already undergone some toxicity testing. Subtracting this 10% from the waivers leaves 0%, 40%, and 50% waivers, respectively, for the oral, inhalation, and dermal routes. For this analysis, we assume 0% for oral and 50% for dermal. For the inhalation route, however, we assume 95% waivers. Inhalation tests for cosmetics typically are performed only in exceptional cases, due to their complexity, cost, and more intensive animal use. In spite of the relevance of this administration route, we assume inhalation evaluations would be extrapolated from other exposure routes in the majority of cases.
Regarding repeated dose studies, Pedersen et al. (2003) estimate that 10% of repeated dose tests may be waived, again, for substances for which no human exposure is likely. That estimate has been recently revised upward for reproductive and developmental toxicity only (Rovida et al., 2011) , confirming that use of waivers was significant in the REACH registration process. As previously noted, this type of waiver does not apply to cosmetic ingredients, because human exposure is a given. Waivers may be allowed based on exposure route. This analysis assumes the same percentage of waivers for repeated dose toxicity tests as for acute toxicity tests: 0% for oral, 95% for inhalation, and 50% for dermal.
Note that oral studies require techniques to extrapolate the oral results to the dermal route (see, for example, IGHRC, 2006) . The reliability of such extrapolations has been questioned (Nohynek et al., 2010) ; however, IGHRC notes that extrapolations must be used despite their limitations, given the predominance of oral data and practical and ethical constraints on conducting new tests for different exposure routes (IGHRC, 2006) . There is general agreement that the situation is not ideal, and that it introduces another extrapolation in addition to the extrapolation of the animal result to a human result.
No non-animal alternatives for the newly proposed evaluations
The proposed Act includes the following language regarding alternative, non-animal tests: "… the Secretary shall (1) The only tests for which alternative, non-animal methods are available are the tests that have already been completed for most substances: eye and skin irritation/corrosion, skin sensitization, and mutagenicity. Eye irritation in vivo and skin sensitization according to OECD TG 429 (LLNA) soon can be fully replaced by in vitro alternatives. Recently, ECVAM endorsed the NT3 cytotoxicity method for the evaluation of non-toxic substances in the oral acute endpoint (EURL EC-VAM, 2013) . This endorsement may have a strong impact on acute toxicity testing for cosmetics as it is fully accepted for the recognition of non-toxic substances. For repeated dose is 10,000, based on expected maximum FDA capacity of 1,000 evaluations each year.
-New ingredients would be tested according to the new standard as part of their pre-market testing. Assuming 600 new ingredients per year, this is 6,000 new ingredients tested over 10 years. Note that although test results could be available for these ingredients, the FDA's capacity to evaluate the results and the required public comment periods would still be limiting factors, so this affects the calculation of the number of ingredients tested, but not the number of ingredients evaluated. The number evaluated is a maximum of 10,000 over 10 years, regardless of the number of ingredients with available test data. -The potential testing scenarios are those described in Section 3.2. -Existing data are available for 15% of new and existing ingredients for all endpoints except phototoxicity and the reproductive toxicity screening test. For phototoxicity, we assume 0.1% existing data. For the reproductive toxicity screening test, we assume 30% for existing ingredients and 15% for new ingredients (see Section 3.4 for details). -Read-across and weight of evidence techniques are used at the percentages reported by ECHA (2011). The exception is repeated dose tests for new ingredients, for which we assume no estimation techniques would be used. Section 3.5 provides more detailed information. The cost for a readacross or weight of evidence evaluation is assumed to be about one-half the cost of the corresponding laboratory test (see Section 2.1.3, "Cost Per Test"). -Waivers for the oral and dermal exposure routes are used at the percentages discussed in Section 3.5. For the inhalation exposure route and for the two-generation reproductive toxicity test and the carcinogenicity test, a waiver of 95% is used, reflecting the rarity with which these are normally requested. -The new evaluations would not necessarily be performed in the US; however, they are new evaluations that otherwise would not be performed. This calculation considers all new evaluations that would be triggered by the proposed Act, regardless of the location at which the evaluation is conducted. Table 15 summarizes the tests for each scenario. Table 16 summarizes the calculations of total cost and animal use for each scenario.
Minimum
In our analysis, the minimum number of ingredients tested by year 10 is 7,200, which is the minimum 1,200 ingredients undergoing evaluation by the FDA plus 6,000 new ingredients undergoing the testing as part of their pre-market testing. For simplicity's sake, we assume that the FDA evaluations will be for existing ingredients (rather than new ingredients), but we recognize that some new ingredients could make the priority list, too, so there may be overlap between the 1,200 evaluations and the 6,000 new ingredients tested. The summaries in Table 16 break out these data to allow readers to test different assumptions.
-The capacity of the FDA to evaluate large numbers of ingredients each year. Let us assume the laboratories can expand capacity to meet the demand, leaving FDA capacity as the main constraint. To evaluate all ingredients in use within 10 years (again assuming only 70% of potential ingredients are used), the FDA would need to evaluate about 1,900 ingredients each year. For comparison, the US EPA's intensive effort to reassess the safety tolerances for pesticide products evaluated 9,700 products within 10 years, or about 1,000 per year. As the EPA notes: "This degree of success for such an ambitious, controversial and complex undertaking is unprecedented" (US EPA, 2012) . For the FDA to meet the 10-year goal would require about double that EPA effort.
In evaluating timelines, an important consideration is when alternative methods will be available for the remaining animal tests. Once alternative methods are available, the pace of evaluations can increase rapidly, because alternative methods for these endpoints are expected to involve high-throughput in vitro screening tests combined with computer models capable of assessing thousands of substances simultaneously. Bottini and Hartung (2009) and Adler et al. (2010) estimated that development and acceptance of alternative test methods would take at least 10 years. The scale of effort has also been compared with the Human Genome Project, which took 13 years. Efforts to develop alternative tests are already under way; therefore, this article assumes 13 years is a reasonable expectation for when the alternative methods could be available and validated. If the proposed Act becomes law, new testing likely would not begin until year 3 or year 4, leaving about 10 years until the alternative tests could replace the animal tests.
With this in mind, consider again the timeline as currently proposed in the Act. If ingredients are evaluated at the minimum rate specified in the Act, about 4% of total ingredients (6% of ingredients in use) would be evaluated within those 10 years. If alternative high-throughput methods are available near year 10, the remaining 96% could be evaluated rapidly through the new methods.
If the FDA achieves the high rate of evaluation that the US EPA accomplished, approximately 1,000 evaluations per year, this would enable the evaluation by year 10 of about 10,000 ingredients, which is about 37% of total ingredients in year 10 (or about half of all ingredients in use in year 10). Again, about year 10, the remaining 63% could be quickly evaluated with new methods.
Pulling it all together: Animal use and evaluation costs under the proposed Act
This section pulls together the information from Section 3 to estimate the animal use and cost for each safety evaluation scenario described in Section 3.2. The analysis uses the following assumptions, summarized in Table 14 : -The minimum number of ingredients evaluated over 10 years is 1,200, based on the Act's minimum requirement of 300 evaluations in the first year and 100 each year thereafter. The maximum number of ingredients evaluated See Section 3.5 for waiver percentages. For the reproductive/developmental toxicity screening study (422) and the prenatal study (414), waiver is set to 0% because it is assumed if these are required, they would be required for all ingredients.
2 RA/WOE, read-across or weight of evidence. See Table 4 in Section 2.1.2 for RA/WOE percentages for first-tier studies (irritation through acute toxicity) and Section 3.5 for percentages for second-tier studies. The cost for the minimum number of ingredients, shown in Table 16 , ranges from about $ 1.7 billion (case 2) to about $ 4.9 billion (case 4) over 10 years. Animal use ranges from about 900,000 (case 1) to about 6.4 million (case 4) over 10 years.
Note that the case with the lowest animal use (case 1) is not the case with the lowest cost (case 2). Case 1 uses about 2 million fewer animals than case 2, but costs about $ 1 billion more. This is because OECD TG 422, at a cost of about $ 145,000 per test, is less expensive than the subchronic tox-This paper does not consider this potential additional testing, because the many unknowns do not allow meaningful analysis. Rather, the following summaries simply identify the general requirements.
Finished cosmetic products
The Act directs the Secretary to presume that a finished cosmetic product is safe if made solely of ingredients found to be safe or safe within limits. The Act does, however, include a provision for testing of a finished cosmetic product at the FDA's discretion: " Penetration enhancers are common ingredients in facial moisturizers and serums, to make the products more effective. Ingredients with low-level estrogenic activity are also fairly common, especially in plant extracts which are increasingly being incorporated into cosmetics as the natural products segment grows rapidly. How finished cosmetic products testing might be implemented is difficult to predict. With more than 500,000 cosmetic products on Amazon alone, the potential may be significant. Offsetting this, the threat of required testing could cause a business, especially a small business, to withdraw the product from the market rather than test, to avoid the cost of testing and possible bad publicity.
Some tests under the proposed Act would take longer than the typical life of a product, making test results moot. The cosmetics industry is extremely dynamic, characterized by rapid turnover of products. Hartung (2008) notes 25% turnover within 6 months. Products are typically reformulated at least every two years, and many are reformulated every year, some even twice a year. This rapid turnover is across brands and cosmetic types. By the time test results were available for a product, the product might not exist anymore.
Ecotoxicity
The proposed Act requires brand owners to submit "(C) Exposure and fate information" for each ingredient in its cosmetics and for each cosmetic owned by the brand (section 615 [a] [2] [C] ). This simple sentence can mean significant additional toxicity studies, including animal testing.
Conclusions
Currently, cosmetic ingredients typically undergo safety testing for eye and skin irritation, skin sensitization, mutagenicity, and acute toxicity; and for UV filters (about 0.1% of ingredients), testing for phototoxicity, too. About 2% of ingredients -mainly hair dyes, colorants, preservatives, and
Maximum
The maximum number of ingredients tested by year 10 is 16,000 ingredients, which is 10,000 existing ingredients plus 6,000 new ingredients. This is about 60% of the total number of ingredients by year 10. The cost ranges from about $ 2.9 billion (case 2) to about $ 9.3 billion (case 4). Animal use ranges from about 1.5 million (case 1) to about 11.5 million (case 4).
Considerations for new ingredients
For both the minimum and maximum analyses, the testing for new ingredients is a dominant factor. It accounts for about 90% of the cost and animal use for the minimum analysis and about 50% for the maximum analysis. The analyses assume manufacturers will test new ingredients according to the Act's standards as part of pre-market testing, even if the ingredient is not scheduled for evaluation by the FDA. Liability concerns, for example, could warrant this. From a financial perspective, however, a present value analysis could indicate that waiting makes more sense, at least for the most cost-intensive tests. If manufacturers choose not to conduct the safety tests pre-market, and instead wait until the FDA requests the data according to the timeline, then the animal and cost numbers shift down significantly. In that case, only 1,200-10,000 ingredients total are tested over 10 years, a maximum of 37% of total ingredients (about 50% of those in use).
Considerations for reproductive toxicity tests
The numbers are sensitive to the choice of reproductive toxicity tests. For example, the prenatal developmental toxicity test in cases 3 and 4 accounts for 8.1 million animals, or 85% of total animals in case 3 and 70% of total animals in case 4, and it accounts for 20% to 30% of the total testing costs.
This analysis assumes that the two-generation reproductive toxicity test (OECD TG 416) or extended one-generation test (OECD TG 443) would be used rarely, if at all. The cost in dollars and animal lives is so large for these tests that they would be difficult to justify for cosmetics ingredients. For example, consider this comparison if OECD 443 or 416 is substituted for the screening test OECD 422 in case 2: -OECD TG 422: 3.1 million to 5.2 million animals; $ 1.7 billion to $ 2.9 billion. -OECD TG 443: 6.3 million to 10.8 million animals; $ 6.0 billion to $ 10.8 billion. -OECD TG 416: 17.2 million to 30 million animals; $ 4.1 billion to $ 7.4 billion. OECD TG 443 is more costly than OECD TG 416 (about $ 650,000-$ 1,000,000/test for 443, depending on the test modules, and about $ 430,000/test for 416), but uses fewer animals. Both are far more costly in dollars and animals than the other options considered in this analysis.
Potential testing not considered: Finished cosmetics and ecotoxicity
The proposed Act focuses on ingredient testing, and that is the focus of this article as well. The Act also notes potential testing for finished cosmetic products and for ecotoxicity.
are similar to those in many technology industries, with constant pressure for new products and reformulations of old products, both to take advantage of new science and to meet changing consumer preferences. Each year, the cosmetics industry worldwide generates hundreds of new ingredients and thousands of new products and reformulations. Under the proposed Act, the FDA would begin evaluations for 300 ingredients in the first year of evaluations, and then begin 100 more evaluations annually each year thereafter. Given there are over 20,000 potential ingredients currently and 500-700 new ingredients added worldwide each year that are either developed in the US or may be imported to the US, this is a timeline that can never catch up with the industry.
If the goal is to evaluate all cosmetic ingredients, the only viable approach would seem to be through new methods currently under development. These techniques use high-throughput cellular-and molecular-based screening tests combined with computational biology. Traditional animal-based evaluation methods are time-consuming and would always lag this industry. High-throughput methods are expected to be available in about 10 years. Even with this 10-year development time, employing new methods is the fastest way to evaluate cosmetics ingredients and, as noted, is the only way to keep up with the rapid product cycles in this industry. If the Act's goal is to be achieved, rapid completion of the development of high-throughput methods will be essential.
Ironically, implementation of the Act could postpone the development of the new testing that would facilitate reaching its goals. The infrastructure for toxicology testing is finite, used both for conducting testing and for developing alternative methods. If more resources are used for the proposed testing, fewer will be available for developing alternative methods, postponing their development.
The rationale for the Act is not stated, but it is likely the precautionary principle. The EU Cosmetics Regulation also invokes the precautionary principle; however, it prohibits animal testing for cosmetics. The proposed US Act, in asking for expanded animal testing until alternative methods are available, conflicts with the EU Cosmetics Regulation. If the proposed US Act passes, it is not clear whether cosmetics companies will need two different types of products: one with animal testing for the US market and one without animal testing for the EU market.
In this article, we have focused on numbers, but it is important to ask whether the expanded testing in the Act, and the consequent impacts on the cosmetics industry, the toxicology field, and animal welfare, are justified for cosmetics. We hope others will take up this discussion.
UV filters -are intended to be reactive or biologically active and may undergo additional, repeated dose studies to assess systemic and reproductive toxicity.
The annual cost and animal use for ingredient safety evaluations in the US are estimated here at $ 5.4 million and 2,700 animals. The proposed US Safe Cosmetics Act would affect testing worldwide, however, so the worldwide baseline number is also important. The current totals worldwide for cosmetic ingredients are estimated to be $ 54 million and 27,000 animals.
Under the proposed US Safe Cosmetics Act, every ingredient would be evaluated to develop its NOAEL from a repeated dose study. Until alternative methods are available for this (about 10 years), the most likely study, based on current guidance documents, would be the subchronic 90-day repeated dose toxicity study (SCCS, 2010; SCCP, 2012) . We evaluated four potential testing scenarios to estimate cost and animal use.
In the first scenario, ingredients would undergo basic tier 1 evaluations plus the subchronic study. Over 10 years, this would cost about $ 2.8-$ 5.0 billion and use about 900,000 to 1.5 million animals. Annually, this would be about $ 280-$ 500 million and 90,000 to 150,000 animals.
Optionally, a reproductive toxicity screening study (OECD TG 422) could replace the subchronic study, with the 28-day repeated dose portion of the screening study used to derive the NOAEL. We consider this scenario less likely, because the subchronic study is preferred for obtaining the NOAEL. In this scenario, the cost over 10 years is $ 1.7-$ 2.9 billion and 3.1 million to 5.2 million animals. Annually, this is $ 170-$ 290 million and 310,000 to 520,000 animals.
A third scenario is the same as the first, but adds the prenatal developmental toxicity study (OECD TG 414). The prenatal study would be in addition to the subchronic study. The resulting total cost is $ 3.7-$ 6.9 billion and 5.4 million to 9.7 million animals. Annually, the estimates are $ 370-$ 690 million and 540,000 to 970,000 animals.
Finally, we considered a scenario in which guidelines currently recommended for reactive and biologically active ingredients (about 2% of ingredients) would be applied to all ingredients. This could involve a cost-and animal-intensive multi-generation test, OECD TG 416 or 443, but we assume that test would be requested rarely, for only 3% of ingredients. For this case, the cost over 10 years is $ 4.9-$ 9.3 billion and 6.4 million to 11.5 million animals. The corresponding annual numbers are $ 490-$ 930 million and 640,000 to 1.2 million animals.
An analysis such as this relies on many assumptions, some with a high degree of uncertainty. Within the reasonable bounding range for each assumption, however, it is clear that, no matter which assumption we use within that range, the cost of the proposed evaluations is much higher compared with current practice, both in terms of dollars and animal use.
A striking mismatch exists between the multi-year evaluations of ingredients under the Act and the rapid product development cycles in the cosmetics industry. These cycles
